Patient Derived Xenograft/PDX Models Market report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share.
PDX Models Market Is Projected To Grow At A CAGR Of 16.7%
The global PDX models market is estimated to grow at a CAGR of 16.7% from 2017 to 2022, to reach USD 167.6 million.
Get Sample Copy Here@ www.reportsnreports.com/contacts/r…aspx?name=1187511
The key factors driving the growth of the overall PDX models market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. However, the high cost of personalized PDX models and stringent guidelines regarding the ethical use of animals in cancer research are expected to restrain the growth of this market during the forecast period.
The respiratory tumor models segment is projected to grow at the highest CAGR during the forecast period
Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck cancer, sarcoma, and melanoma.
During the forecast period, the respiratory tumor models segment is expected to register the highest CAGR. Growth in this segment is mainly driven by the increasing focus of market players on generating lung cancer PDX models, which could lead to a breakthrough in lung cancer treatment, as lung cancer is the leading cause of cancer-related deaths across the globe.
Access Patient Derived Xenograft/PDX Models Market 2017-2022 Spreads Across 181 Pages Profiling 10 Companies and Supported with 192 Tables And 29 Figures Available at www.reportsnreports.com/contacts/d…aspx?name=1187511
*Top 15 companies analyzed for this studies are - Crown Bioscience Inc. (US), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Charles River Laboratories, International, Inc. (US), WuXi AppTec (China), ONCODESIGN (France), EPO Berlin-Buch GmbH(Germany), Shanghai LIDE Biotech Co., Ltd. (China), Xentech (France), Horizon Discovery Group PLC (UK), Pharmatest Services Ltd. (Finland), Hera BioLabs (US), Urolead (France), Xenopat (Spain), Bioduro (US)
- Mice/rat models and service companies and distributors
- Animal care product manufacturers and suppliers
- Out–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology)
- In–licensing life sciences companies (pharmaceutical/biopharmaceutical/biotechnology)
- Clinical research organizations
- Academic institutes
- Government and private research institutes
- Medical research centers
- Public and private animal health agencies
- Animal care associations
- Business consultancies
- Venture capitalists
Key point from table of content
6 Patient Derived Xenograft Models Market, By Type
6.2 Mice Models
6.3 Rat Models
7 Patient Derived Xenograft Models Market, By Tumor Type
7.2 Gastrointestinal Tumor Models
7.3 Gynecological Tumor Models
8 Patient Derived Xenograft Models Market, By Application
8.2 Preclinical Drug Development and Basic Cancer Research
8.3 Biomarker Analysis
Browse Here for full Report with TOC: www.reportsnreports.com/reports/11…t-st-to-2022.html